Jensen Huang, with beautiful Pichai and others, meet Reshma Kewalli, who join the list of 100 most powerful people in 2025. world News

Born in Mumbai and now Reshma Kewalmani, CEO of Wartax Pharmaceuticals, has earned a prestigious place in the 2025 list of the 100 most powerful people in the business. Rank at number 62, she is the only Indian original woman CEO of a major American biotechnology company to make a list of this year. While global names like Mark Zuckerberg, Sundar Pichai, Satya Nadella, and Mukesh Ambani also appear in the list, kewalman’s recognition is a monumental achievement for women in science -led industries. A physician in Boston Hospitals topped the $ 110 billion biotech company, a notable journey of leadership, innovation and impact in the global healthcare scenario.

Who is Reshma Kewalmani: Mumbai -born Biotech CEO Fortune list of most powerful business leaders in 2025

Born in Mumbai, Reshma Kewalmani moved to the United States when she was just 11 years old. With a passion for the drug, he chased his education and began his career as a doctor at Massachusetts General Hospital and Brigham and Women’s Hospital – two of the most prestigious medical institutions in the US. His early experiences in clinical settings set a strong base for his future in biotechnology, where patient-focused care and scientific innovations run by hand.In 2020, Reshma Kewala Mani made history by becoming the first woman to lead a major American biotechnology company. She joined the Wartax Pharmaceuticals in 2017 and quickly climbed as the Chief Medical Officer in 2018 and then the CEO two years later. His appointment was more than an individual milestone – it was a symbol of a success in gender representation in the region of men dominated by men, especially at the executive level.

The vertex pharmaceuticals under Reshma Kewalmani grows up to $ 110 billion

Under his leadership, vertex pharmaceuticals have increased a biotech powerhouse, priced at $ 110 billion. The company is known for its innovations in the treatment of cystic fibrosis and continues to expand its pipeline with bold research in rare diseases. Most particularly in 2025, the company received FDA approval for a revolutionary non-opioid pain treatment, Zernavax. This approval is being seen as a milestone in the global battle against Opioid epidemic – a crisis that has destroyed millions.The unique edge of Kewalmani as a licensed physician gives him a dual perspective- clear and strategic. Unlike several Biotech CEOs, which come purely from a professional background, it brings clinical experience for boardroom decisions. This medical insight has been important in shaping the patient-first approach of the vertex for the development and innovation of the drug, which has further enhanced its global reliability and effect.

Reshma Kewalmani is ranked 62 in Fortune’s list of influential business leaders of Fortune

Now in their second version, the 100 most powerful people of Fortune celebrate those in business who affect the impact, run innovation, and shape the future of the industry – not only the highest net worth. In Rank 62, the entry of Keywalmani is a clear indication of their growing stature in international trade and biotech communities.Top rank facility this year:

While Reshma Kewal Mani cannot be a domestic name yet, her work is changing life. Their calm but influential leadership style focuses on meaningful science, global health and diverse representation in leadership. This is her first time in the Fortune list, and it reflects the global acceptance of her contribution not only for business, but also through science.Also read Earthquake risk in Canada! Yukon Fault shows signs of awakening after 12,000 years, threatening thousands